Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

onse to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

For more information about docetaxel (taxotere(R)) please visit http://www.taxotere.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities comm
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... in its Phase 2 FDG-PET clinical trial of VIA-2291. ... was carried out at five sites in the US ...
(Date:12/3/2009)... Caliper Life Sciences, Inc. (Nasdaq: CALP ), ... discovery and life sciences research, today introduced Living Image ... Image software drives the more than 800 Caliper IVIS ... features advanced spectral unmixing tools to enhance fluorescent sensitivity ...
(Date:12/2/2009)... 2 Reportlinker.com announces that a new ... catalogue: ,, Neurostimulation - A Global ... ,, The world neurostimulation market stands ... population, and the resultant rise in age-related ...
(Date:12/2/2009)... 2 The world,s first concept demonstration ... replace a petrochemically produced ingredient in the manufacture of ... Copenhagen, Denmark, this week. One tire will be on ... at the Copenhagen International Airport throughout December 21, while ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3
... Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... appointment of Mrs. Janneke de Wal, M.D., as,Director ... Anthony J.,Gringeri, Ph.D., Chief Operating Officer. She will ... De Wal has over 20 years of experience ...
... kinds of bacteria to produce hydrogen in a bioreactor, with ... to an article in the August issue of Microbiology ... can be used to scavenge precious metals from spent automotive ... energy. , Hydrogen has three times more potential energy by ...
... CALL DATE: Wednesday, Aug. 6, 2008 TIME: ... Dr. Candace Kendle, Chairman and ... conference call and,simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. ... June 30, 2008. A,question and answer session will follow., Webcast ...
Other Biology Technology:AMT Appoints Director Global Marketing and Sales 2AMT Appoints Director Global Marketing and Sales 3Fuel from food waste: bacteria provide power 2Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2
(Date:12/4/2009)... Ore. According to an analysis of statewide data ... than $50,000 a year were more than three times ... providers because of their insurance status during pregnancy and ... was also three times more likely among mothers with ...
(Date:12/4/2009)... is available in German . , A ... Ageing could help to understand the positive effect of dietary ... flies and mice) have shown that dietary restriction increases longevity, ... So the female fruit fly reproduces less frequently with a ...
(Date:12/3/2009)... Hausen and his co-workers discovered that specific types of ... out how these pathogens cause cells to degenerate. It ... proteins E6 and E7. Both proteins switch off different ... Professor Dr. Frank Rsl and his co-workers at DKFZ ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2How nutrition affects healthy aging 2Papillomavirus silences innate immune response 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 1The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 2The Presidents Council on Physical Fitness and Sports Announces 2009 Lifetime Achievement Award Winners 49257 3Squeamish Colorado Dental Patients Get Drilled By Self Interested Regulators 49254 1Squeamish Colorado Dental Patients Get Drilled By Self Interested Regulators 49254 2Squeamish Colorado Dental Patients Get Drilled By Self Interested Regulators 49254 3Actuaries Provide Capitol Hill Briefing to Explore Health Care Reform Components 49250 1Actuaries Provide Capitol Hill Briefing to Explore Health Care Reform Components 49250 2
... PGC-1 mediates effects of nutrition on blood disease porphyria ... a molecular explanation for the episodic attacks of irrational ... have afflicted "Mad" King George III, the British ruler ... the Revolutionary War. , The mental and physical symptoms ...
... off the immune suppression that stymies attempts to fight cancer ... (BCM) at Houston. , In a report in today's issue ... the BCM Center for Cell and Gene Therapy and Department ... turn off the function of a special group of T ...
... is now a chief of an immunology laboratory of the ... the past few years for the experts in the understanding ... the "danger model," suggesting that the immune system is more ... cell's death than with the introduction of foreign invaders, such ...
Other Biology News:Attacks of King George III's madness linked to key metabolism molecule 2Attacks of King George III's madness linked to key metabolism molecule 3Improving the potential of cancer vaccines 2Researchers seek to discover what really happens when a virus enters the body 2Researchers seek to discover what really happens when a virus enters the body 3
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
ANTI PIG LDH H4...
... use in refrigerators, freezers, or liquid nitrogen. Conveniently sized ... for color coding to project, user, lab, etc. Holes ... cool air circulation. Supplied with 10 x 10 (11.6 ... Box dimensions: 13 x 13 x 5.1 cm H ...
Biology Products: